Lentz, M. R. : Phylogeny of oncology, Molecular Biotherapy, 2:137-144, Sep 1990.
Lentz, M. R. : Continuous whole blood ultrafiltration in patients with metastatic cancer.
Journal Biologic Response Modifiers, 8:511-527, 1989.
Lentz, .R. and Saltonstahl,W.P. : Apheresis of low molecular weight protein fraction and
the onset of labor. Journal of Clinical Apheresis, 5:62-67, 1990
Gutanaga,T., Lentz,M.R.,Masunaka, I., Tomich,J., et al.: Identification of TNF – LT
blocking factors in the serum and ultrafiltrates of human cancer patients.
Lymphokine Research, 9:225-229, 1990.
Schall,T. J., Lewis,M., Gatanaga,T.,Granger,G.A., Lentz,M.R., et al.
Molecular cloning and expression of a receptor for human tumor necrosis
factor. Cell, 61:361 – 370, April 20, 1990.
Gutanaga,T., Lentz, M.R., Tomich, J. Purification and characterization of an inhibitor
(solubleTumor necrosis factor receptor ) for tumor necrosis factor and
lymphotoxin obtained from the serum ultrafiltrates of human cancer
patients. Proceedings National Academy of Science USA, 87:8781 –
8784, November, 1990.
Olssoon, I., Gatanaga,T., Gulberg,U., Lentz, M.R., Granger,G.A.: Tumor necrosis factor
( TNF) binding proteins ( soluble TNF receptor forms ) with possible roles in
inflammation and malignancy. Euro Cytokine Network , 4:169-180, 1993.
Lentz, M. R., Hubbard, W.J., Fischer, C.: Low molecular weight protein apheresis and
regression of breast cancer. Japanese Journal Apheresis Vol 16. No I, 1997.
Lentz, M.R. : Description and identification of a new inhibitor to NK-cell function and to TNF
mediated killing in the serum and ultrafiltration of sera from cancer
patients. Proceedings Keystone Symposium, UCLA, Feb 1990.
Lentz, M.R. : The Role of Therapeutic Apheresis in the Treatment of Cancer : A Review.
Therapeutic Apheresis 1999 3 ( I ):40-49
Lentz, M.R. : Successful Treatment of a Multiple Drug Resistant Gastrointestinal Malignant
Tumor. Publication pending.
Lentz, M.R., Kumar, K.: Reduction of Plasma Levels of Soluble Tumor Necrosis Factor and
Interleukin-2 Receptors by Means of a Novel Immunoadsorption Column.
Therapeutic Apheresis and Dialysis 12(6), 2008:491–499
Lentz, M.R., Bambauer, R., Latza, R.:
Israel, L., Edelstein, R.: In vivo and in vitro studies on nonspecific blocking factors of host
origin in cancer patients. Role of plasma exchange as an immunotherapeutic modality.
Isr J Med Sci 1978; 14:105–30
Langkopf, F., Atzpodien, J.: Soluble tumour necrosis factor receptors as prognostic factors
in cancer patients. Lancet 1994; 344:57-8.
Selinsky, CL, Howell, MD: Soluble tumor necrosis factor receptor type I enhances tumor
development and persistence in vivo. Cell Immunology 2000; 200:81-7.
Elsasser-Beile, U., Gallati, H., Weber, W., Wild, ED, Schulte Monting, J. , von Kleis, S.:
Increased plasma concentrations for type I and II tumor necrosis factor receptors and IL-2-receptors in cancer patients. Tumour Biol 1994; 15:17-24
|